Pantop%2525252525252525252525252525252525252525252520d

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase enzyme system in the gastric parietal cell. It is stable at neutral pH and is activated to its active form in the acidic environment of the secretory canaliculi. ## Primary Indications * Erosive esophagitis associated with GERD. * Maintenance of healing of erosive esophagitis. * Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome). * Short-term treatment of GERD symptoms. ## Adult Dosing * **Erosive Esophagitis:** 40 mg PO or IV once daily for up to 8 weeks. * **GERD Maintenance:** 40 mg PO once daily. * **Hypersecretory Conditions:** Starting dose 40 mg PO twice daily. Doses up to 240 mg/day have been used. Titrate based on clinical need. * **IV Administration:** Typically 40 mg given as a 15-minute infusion once daily. ## Pediatric Dosing * **Erosive Esophagitis (5 years and older):** * 15 kg to <40 kg: 20 mg once daily. * ≥40 kg: 40 mg once daily. * *Note: Duration of therapy is generally restricted to 8 weeks.* ## Dose Adjustments * **Hepatic Impairment:** No specific dose adjustment defined for mild-to-moderate impairment, but clinical monitoring is advised. Data regarding severe impairment is limited. * **Renal Impairment:** No dosage adjustment necessary. ## Contraindications * Known hypersensitivity to pantoprazole or other substituted benzimidazoles (e.g., omeprazole, lansoprazole). * Concurrent use with rilpivirine-containing products. ## Adverse Effects * **Common:** Headache, diarrhea, nausea, abdominal pain, vomiting, flatulence. * **Serious:** *Clostridioides difficile*-associated diarrhea, bone fractures (hip, wrist, spine with long-term use), hypomagnesemia, Vitamin B12 deficiency (with prolonged use), acute interstitial nephritis, and cutaneous/systemic lupus erythematosus. ## Key Drug Interactions * **pH-Dependent Drugs:** May decrease absorption of ketoconazole, atazanavir, iron salts, and mycophenolate mofetil. * **CYP2C19/3A4:** Pantoprazole is metabolized by CYP2C19; although less prone to interactions than omeprazole, use caution with drugs requiring acidic gastric pH for bioavailability. * **Methotrexate:** May increase serum levels/toxicity of methotrexate, particularly in high-dose therapy. ## Monitoring * Monitor for signs of *C. difficile* infection (unresolved diarrhea). * In long-term therapy (>1 year), monitor magnesium levels and consider B12 supplementation if clinically indicated. * Monitor renal function if clinical signs of interstitial nephritis occur. ## Clinical Pearls * **Administration:** PO tablets should be swallowed whole; do not split, crush, or chew. Can be taken with or without food. * **IV Transition:** Patients should be transitioned to oral therapy as soon as they are able to tolerate oral medication. * **Inappropriate Use:** PPIs are frequently over-prescribed for patients without a clear gastrointestinal indication; evaluate the necessity of therapy regularly, especially in the elderly. * **Hypersecretory conditions:** Dosing for Zollinger-Ellison is highly individualized and should be based on clinical response and acid output measurements; always consult local institutional protocols for titration schedules. *** **Educational Disclaimer:** This information is for educational purposes only. Clinical practice guidelines and drug labels are subject to change. Always verify current prescribing information, institutional protocols, and patient-specific factors before administering any medication.